Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:80199
Name colorectal carcinoma
Definition A colorectal cancer that arises from the colon or rectum and invades through the muscularis mucosa into the submucosa.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer intestinal cancer large intestine cancer colorectal cancer colorectal carcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
EML4 - ALK Crizotinib colorectal carcinoma predicted - sensitive detail...
EML4 - ALK Lorlatinib colorectal carcinoma predicted - sensitive detail...
MSH6 F1088Lfs*5 MSH6 Y1256* MSH6 A1320Sfs*5 Nivolumab colorectal carcinoma predicted - sensitive detail...
BRAF V600E Palbociclib + PD-0325901 colorectal carcinoma no benefit detail...
BRAF V600E Gedatolisib + Palbociclib colorectal carcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02611024 Phase Ib/II Irinotecan + Lurbinectedin Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors Recruiting USA | ESP 0
NCT02977156 Phase I Ipilimumab + JX-594 Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. (ISI-JX) Completed FRA 0
NCT03264664 Phase I E7386 Study of E7386 in Participants With Selected Advanced Neoplasms Recruiting USA | GBR 0
NCT03287427 Phase I TetMYB + Tislelizumab MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial (MYPHISMO) Completed AUS 0
NCT03428958 Phase I A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment Completed USA | GBR | FRA 0
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Completed USA 0
NCT03752398 Phase I Izuralimab A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) Active, not recruiting USA 0
NCT03849469 Phase I Pembrolizumab + XmAb22841 XmAb22841 A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) Completed USA 0
NCT03957096 Phase I SGN-CD47M A Safety Study of SGN-CD47M in Patients With Solid Tumors Terminated USA 0
NCT04060407 Phase Ib/II CD24Fc + Ipilimumab + Nivolumab CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) (CINDI) Withdrawn USA 0
NCT04096638 Phase I Nivolumab + SB 11285 SB 11285 Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04672434 Phase I Sym021 + Sym024 Sym024 Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Active, not recruiting USA | CAN 0
NCT04735796 Phase I LM-102 Study of LM-102 in Subjects in Advanced Tumors Terminated USA 0
NCT04752215 Phase I BI 765049 + Ezabenlimab BI 765049 A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface Recruiting USA | CAN 0
NCT04793958 Phase III Adagrasib + Cetuximab Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 20
NCT04975256 Phase I Adagrasib + BI 1701963 Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) Completed USA 0
NCT05001516 Phase Ib/II TPX-4589 Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors Completed USA 0
NCT05217446 Phase II Pembrolizumab Cetuximab + Encorafenib + Pembrolizumab A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer (SEAMARK) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 6
NCT05625412 Phase I CC-90001 + Nivolumab Capecitabine + CC-90001 CC-90001 CC-90001 + Docetaxel A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors Recruiting USA | ITA | FRA | ESP | CAN | AUS 3
NCT05700656 Phase Ib/II Capecitabine + Galunisertib Galunisertib Combined With Capecitabine in Advanced CRC With PM Not yet recruiting NLD 0
NCT05786924 Phase I BDTX-4933 A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers Recruiting USA 0
NCT05958199 Phase I NPX267 Treatment With NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 Recruiting USA 0
NCT06105021 Phase Ib/II AFNT-211 Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor Recruiting USA 0
NCT06120075 Phase I AB801 AB801 + Docetaxel AB801 + Docetaxel + Zimberelimab A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (ARC-27) Recruiting USA 0
NCT06216561 Phase I CEND-1 Intraperitoneal LSTA1 in CRS-HIPEC Recruiting USA 0
NCT06240728 Phase I NPX887 A Study of NPX887 for Participants With Solid Tumors Known to Express HHLA-2/B7-H7 Recruiting USA 0